Asahi Kasei Corporate Venture Capital

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Swing develops safe and effective digital therapeutics for chronic conditions, partnering with top researchers to create evidence-based treatments. Their solutions empower patients to manage their illnesses, improving health outcomes.

Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Aerobiotix is a privately held company focused on creating and producing proprietary environmental management devices designed for institutional healthcare, home health, and commercial applications. The company specializes in innovative technologies aimed at efficiently eliminating airborne viruses, bacteria, and spores, thereby optimizing indoor environments. By addressing critical health concerns related to air quality, Aerobiotix provides solutions that enhance safety and well-being in various settings.

Hazel Technologies develops and produces postharvest technologies that extend the shelf life of fresh produce. The company’s core product is a carton insert that releases ethylene inhibitors, such as 1‑MCP, to slow respiration and aging in fruits and vegetables, thereby reducing spoilage and waste. In addition to its hardware, Hazel offers horticultural consulting and supply‑chain solutions that help growers, shippers, and retailers optimize storage conditions and inventory management. Founded in 2015, the company is headquartered in Chicago, Illinois, with an additional site in Salinas, California. Its technologies have been validated by academic research and supported by USDA funding, positioning Hazel as a key player in improving the efficiency and sustainability of the fresh‑produce supply chain.

Firework provides a video commerce platform that enables businesses to stream videos directly on their websites. Its features include in-video shopping, lead generation, live streaming events, and AI-powered video assistants, allowing brands to engage visitors and boost conversions.

Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., known as Dami & Xiaomi, operates an online platform dedicated to supporting children with autism spectrum disorders. Established in 2014 and based in Shenzhen, China, the company offers a range of integrated services including rehabilitation, educational support, parent training, online courses, and science information. Dami & Xiaomi aims to address the needs of children with developmental disorders, focusing on effective strategies to help them manage autism and promote healthy growth. Through its comprehensive platform, it provides essential resources to empower parents and caregivers in their efforts to support their children's development.

Hazel Technologies develops and produces postharvest technologies that extend the shelf life of fresh produce. The company’s core product is a carton insert that releases ethylene inhibitors, such as 1‑MCP, to slow respiration and aging in fruits and vegetables, thereby reducing spoilage and waste. In addition to its hardware, Hazel offers horticultural consulting and supply‑chain solutions that help growers, shippers, and retailers optimize storage conditions and inventory management. Founded in 2015, the company is headquartered in Chicago, Illinois, with an additional site in Salinas, California. Its technologies have been validated by academic research and supported by USDA funding, positioning Hazel as a key player in improving the efficiency and sustainability of the fresh‑produce supply chain.

Feldan Therapeutics specializes in intracellular drug delivery using its patented Feldan Shuttle technology. This platform enables rapid, safe, and efficient transport of therapeutic agents into cells, with a focus on developing treatments for serious diseases such as skin and lung conditions.